Bosutinib in (Ph+) Chronic Myelogenous LeukemiaBosutinib in (Ph+) Chronic Myelogenous Leukemia

Owing to its favorable toxicity profile and its high antileukemic activity, bosutinib is a promising novel treatment option for patients with CML. Therapeutic Advances in Hematology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news